Posted inBiotechnology
Posted inBiotechnology
JPM25: GSK’s CSO shares science strategy behind deal-making, plus plans to build off GLP-1s—but not for obesity
Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in…













